NVCT (Nuvectis Pharma) Moat Score: 3/10 (As of Jun. 29, 2026)


NVCT Nuvectis Pharma Inc NVCT
22 GF Score
Price $28.52
! 2 Warning Signs
View Full Analysis

What is Nuvectis Pharma Moat Score?

Nuvectis Pharma NVCT +4.93% 22 Moat Score is 3 as of Jun. 29, 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,401 Biotechnology companies, Nuvectis Pharma ranks better than 75.52% on this metric.

Nuvectis Pharma has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Nuvectis Pharma has No Moat: Nuvectis Pharma Inc lacks significant market leadership and customer loyalty. The company does not have strong intellectual property or regulatory barriers, resulting in weak and transient competitive advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Nuvectis Pharma might have No Moat - Very weak/transient advantages.

Nuvectis Pharma  (NAS:NVCT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Nuvectis Pharma Moat Score Related Terms

NVCT vs AURA, OCS, CADL: Moat Score Comparison

For the Biotechnology subindustry, Nuvectis Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's Moat Score falls into.


NVCT
22GF Score
Nuvectis Pharma Inc NVCT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Nuvectis Pharma (NVCT) has a Moat Score of 3 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Nuvectis Pharma ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Nuvectis Pharma's Moat Score too high?
Nuvectis Pharma's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Nuvectis Pharma's value of 3 is 50% above this industry median. Based on the distribution chart, Nuvectis Pharma ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's Moat Score compare to AURA and OCS?
According to the Biotechnology industry distribution chart, Nuvectis Pharma ranks #343 out of 1401 companies for Moat Score. This places Nuvectis Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Nuvectis Pharma's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvectis Pharma's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvectis Pharma's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Nuvectis Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current Moat Score is 3 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvectis Pharma Business Description

Address 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score

Get the complete analysis for NVCT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.52
Price